2 days ago · OSAKA, Japan, Jan 30, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) is pleased to announce that its novel investigational respiratory syncytial virus (RSV) oral antiviral candidate S-337395, which is being jointly developed with UBE Corporation (Head office: Minato-ku, Tokyo; President and Representative ...

Shionogi Announces Positive Results from Phase 2 Human Challenge Trial of Respiratory Syncytial Virus (RSV) Oral Antiviral Candidate S-337395 ⚫ Statistically Significant Reduction in Viral Load Confirmed in Clinical Trial ⚫ Primary Endpoint Achieved ⚫ In the highest dose group, there was an 88.94% reduction in viral load (P<0.0001) ...

2 days ago · Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese pharmaceutical’s candidate, S-337395, saw success in reducing the impact of the virus as part of a Phase II human challenge study, a type of ...

2 days ago · In adults aged 60 years and older, the seasonal global incidence of RSV infection is 16.11 cases per 1000 people. 7 RSV can also severely impact the elderly, with an estimated 27.44% developing pneumonia and 24.48% requiring hospitalization 6. About Shionogi in Infectious Disease

S-217622 is made by a company called Shionogi. It is a type of antiviral drug called a protease inhibitor. It stops the virus that causes COVID-19 (SARS-CoV-2) from multiplying. This means there could be fewer viruses for the body to fight, and it may help participants get better faster.

Feb 15, 2023 · S-217622 suppresses SARS-CoV-2 replication by inhibiting the function of a key virus protein known as 3CL protease. The antiviral reduced COVID-19 symptoms in people with mild-to-moderate COVID-19, regardless of risk factors or vaccination status, according to results shared by Shionogi from a Phase 3 clinical trial conducted mainly in Japan. S ...

The Shionogi S-217622 Study, which compares an investigational antiviral drug called S-217622, or ensitrelvir, to a placebo to see if it will help adults in the hospital with COVID-19 respiratory infection get better and go home faster.

2 days ago · Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. The study saw 114 healthy adults inoculated with the virus and ...

1 day ago · Shionogi’s investigational RSV oral antiviral, S-337395, met its primary endpoint in a phase 2 human challenge trial. The highest dose group achieved an 88.94% reduction in viral load (P<0.0001) and showed a significant improvement in clinical symptoms, demonstrating strong antiviral efficacy.

2 days ago · About RSV infection 】 RSV is present worldwide without any geographical or climatic bias. It is characterized by having the greatest impact on vulnerable infants in all regions and by recurring annually, especially in urban areas. Each year in the U.S., RSV leads to approximately: 2.1 million outpatient (non- hospitalization) visits among